| Lawrence Allen Hansen, MD | |
|
7445 Allen Rd, Suite 190, Allen Park, MI 48101-1993 | |
| (313) 382-2184 | |
| (313) 382-2189 |
| Full Name | Lawrence Allen Hansen |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 7445 Allen Rd, Allen Park, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699957357 | NPI | - | NPPES |
| 0825978 | Other | MI | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 4301407500 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lawrence Allen Hansen, MD 7445 Allen Rd, Suite 190, Allen Park, MI 48101-1993 Ph: (313) 382-2184 | Lawrence Allen Hansen, MD 7445 Allen Rd, Suite 190, Allen Park, MI 48101-1993 Ph: (313) 382-2184 |
News Archive
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.
Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. It is a leading cause of death and the burden is expected to grow worldwide due to the growth and aging of the population, mainly in less developed countries, in which about 82% of the world's population resides. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths simply due to the growth and aging of the population. Current cancer therapy approaches are based in surgery, radiotherapy and chemotherapy, being the chemotherapy the one that shows the greater efficiency for cancer treatment, mainly in more advanced stages. A major problem with this conventional chemotherapy is its toxicity and it also destroys healthy tissues resulting in systemic toxicity besides beneficial characteristics of killing cancer cells. Anticancer drugs also destroy healthy tissues resulting in systemic toxicity.
A Saint Louis University cardiologist called upon the U.S. Food and Drug Administration (FDA) today to reconsider a strong warning it recently placed on a diagnostic tool, stating that the warning could prevent doctors from detecting life-threatening cardiac events.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.
› Verified 4 days ago
Dr. Mohamed Mahmoud Jaber, M D General Practice Medicare: Accepting Medicare Assignments Practice Location: 4617 Allen Rd, Allen Park, MI 48101 Phone: 313-779-8113 |